Lead Product(s) : Cilengitide
Therapeutic Area : Oncology
Study Phase : Phase II
Sponsor : Brain Tumor Trials Collaborative | EMD Serono
Deal Size : Inapplicable
Deal Type : Inapplicable
Ph II Cilengitide Plus Bevacizumab for Recurrent Glioblastoma (GBM)
Details : Undisclosed
Product Name : Undisclosed
Product Type : Protein
Upfront Cash : Inapplicable
February 04, 2013
Lead Product(s) : Cilengitide
Therapeutic Area : Oncology
Highest Development Status : Phase II
Sponsor : Brain Tumor Trials Collaborative | EMD Serono
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Cilengitide
Therapeutic Area : Oncology
Study Phase : Phase II
Sponsor : Merck Group
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : Undisclosed
Product Name : Undisclosed
Product Type : Protein
Upfront Cash : Inapplicable
January 25, 2012
Lead Product(s) : Cilengitide
Therapeutic Area : Oncology
Highest Development Status : Phase II
Sponsor : Merck Group
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Cilengitide
Therapeutic Area : Nephrology
Study Phase : Phase I
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Pharmacokinetics in Subjects With Renal Impairment
Details : Undisclosed
Product Name : Undisclosed
Product Type : Protein
Upfront Cash : Inapplicable
January 05, 2012
Lead Product(s) : Cilengitide
Therapeutic Area : Nephrology
Highest Development Status : Phase I
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Cilengitide
Therapeutic Area : Oncology
Study Phase : Phase II
Sponsor : Merck Group
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : Undisclosed
Product Name : Undisclosed
Product Type : Protein
Upfront Cash : Inapplicable
May 17, 2010
Lead Product(s) : Cilengitide
Therapeutic Area : Oncology
Highest Development Status : Phase II
Sponsor : Merck Group
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Cilengitide
Therapeutic Area : Oncology
Study Phase : Phase I
Sponsor : Merck Group
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : Undisclosed
Product Name : Undisclosed
Product Type : Protein
Upfront Cash : Inapplicable
May 07, 2010
Lead Product(s) : Cilengitide
Therapeutic Area : Oncology
Highest Development Status : Phase I
Sponsor : Merck Group
Deal Size : Inapplicable
Deal Type : Inapplicable